AR036970A1 - Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion - Google Patents
Composicion farmaceutica androgenica y metodo para el tratamiento de la depresionInfo
- Publication number
- AR036970A1 AR036970A1 ARP030100900A ARP030100900A AR036970A1 AR 036970 A1 AR036970 A1 AR 036970A1 AR P030100900 A ARP030100900 A AR P030100900A AR P030100900 A ARP030100900 A AR P030100900A AR 036970 A1 AR036970 A1 AR 036970A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- steroid
- composition
- depressive disorder
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Métodos, equipos, combinaciones y composiciones para tratar, prevenir o reducir el riesgo de desarrollar un trastorno depresivo, o los síntomas asociados, o relacionados con un trastorno depresivo, en un sujeto que lo necesita. Método de administración de un esteroide de la vía de síntesis de la testosterona, por ejemplo testosterona, a un sujeto que lo necesita. Los métodos, equipos combinaciones y composiciones pueden utilizarse en combinación con otros agentes farmacéuticos que incluyen agentes efectivos para tratar, prevenir o reducir el riesgo de desarrollar un trastorno depresivo en un sujeto. Reivindicación 1: Uso de una cantidad efectiva para un trastorno depresivo de una composición aplicada a un área de la piel de un sujeto para la liberación de un esteroide de la vía de síntesis de la testosterona al suero sanguíneo del sujeto para la fabricación de un medicamento para tratar, prevenir o reducir el riesgo de desarrollar un trastorno depresivo en un sujeto que lo necesita, la composición comprende: a) entre alrededor de 0,01% y alrededor de 70% del esteroide de la vía de síntesis de la testosterona; b) entre alrededor de 0,01% y alrededor de 50% de un agente mejorador de la penetración; c) entre alrededor de 0,01% y alrededor de 50% de un agente espesante; y d) entre alrededor de 30% y alrededor de 98% de un alcohol inferior; en donde la composición es capaz de liberar el esteroide después de aplicar la composición a la piel a una tasa y duración que suministre al menos aproximadamente 10 microg por día del esteroide al suero sanguíneo del sujeto; y los porcentajes están tomados en base a una relación peso a peso de la composición. Reivindicación 5: El uso de la reivindicación 4, en donde el agente mejorador de la penetración es el miristato de isopropilo. Reivindicación 42: Una composición farmacéutica para la administración a la piel de un sujeto, que comprende: i) entre alrededor de 0,01% y alrededor de 70% de un esteroide de la vía de síntesis de la testosterona; ii) entre alrededor de 0,01% y alrededor de 50% de un agente mejorador de la penetración; iii) entre alrededor de 0,01%y alrededor de 50% de un agente espesante; iv) entre alrededor de 30% y alrededor de 98% de un alcohol inferior; y v) un agente que comprende un agente antidepresivo, un inhibidor de la síntesis de la globulina fijadora de hormonas sexuales, o una hormona estrogénica; y en donde la composición es capaz de ser administrativa a una área de la piel del sujeto para suministro del esteroide de la vía de síntesis de la testosterona y el agente terapéutico al suero sanguíneo del sujeto, y es capaz de liberar el esteroide después de aplicar la composición a la piel a una tasa y duración que suministre al menos aproximadamente 10 microg por día del esteroide al suero sanguíneo del sujeto y los porcentajes están tomados en base a una relación peso a peso de la composición y la cantidad del esteroide y la cantidad del agente terapéutico juntas conforman una cantidad efectiva para un trastorno depresivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/098,232 US20040002482A1 (en) | 2000-08-30 | 2002-03-15 | Androgen pharmaceutical composition and method for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036970A1 true AR036970A1 (es) | 2004-10-20 |
Family
ID=34192609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100900A AR036970A1 (es) | 2002-03-15 | 2003-03-14 | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20090318398A1 (es) |
| AR (1) | AR036970A1 (es) |
| BR (1) | BR0308584A (es) |
| EA (1) | EA007431B1 (es) |
| HK (1) | HK1082677A1 (es) |
| IL (3) | IL163981A0 (es) |
| NO (1) | NO345056B1 (es) |
| NZ (1) | NZ535368A (es) |
| OA (1) | OA12856A (es) |
| TW (1) | TWI339122B (es) |
| UA (1) | UA80964C2 (es) |
| ZA (1) | ZA200407403B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| ATE319426T1 (de) | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| SI1937276T1 (sl) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Izboljšani testosteronski gel in postopek uporabe |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861764A (en) * | 1986-11-17 | 1989-08-29 | Macro Chem. Corp. | Percutaneous absorption enhancers, compositions containing same and method of use |
| US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| IE62715B1 (en) * | 1989-03-10 | 1995-02-22 | Endorecherche Inc | Combination therapy for treatment of estrogen sensitive diseases |
| US5788983A (en) * | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| JP4102901B2 (ja) * | 1994-09-14 | 2008-06-18 | スリーエム カンパニー | 経皮薬剤導入用マトリックス |
| US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
| US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
| US6019997A (en) * | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
| WO1998034621A1 (en) * | 1997-02-07 | 1998-08-13 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
| JP4139860B2 (ja) * | 1997-11-10 | 2008-08-27 | ストラカン インターナショナル リミティッド | 浸透増強および刺激減少システム |
| US6200591B1 (en) * | 1998-06-25 | 2001-03-13 | Anwar A. Hussain | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction |
| US5880117A (en) * | 1998-07-13 | 1999-03-09 | Arnold; Patrick | Use of 4-androstenediol to increase testosterone levels in humans |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| PL360992A1 (en) * | 2000-08-30 | 2004-09-20 | Unimed Pharmaceuticals,Inc. | Method of increasing testosterone and related steroid concentrations in women |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20040072810A1 (en) * | 2001-11-07 | 2004-04-15 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
| FR2848112B1 (fr) * | 2002-12-10 | 2007-02-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations |
| FR2851470B1 (fr) * | 2003-02-20 | 2007-11-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse |
| US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| SI1937276T1 (sl) * | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Izboljšani testosteronski gel in postopek uporabe |
| JP4148988B2 (ja) * | 2006-09-11 | 2008-09-10 | 積水化学工業株式会社 | 貼付剤 |
-
2003
- 2003-03-14 BR BR0308584-8A patent/BR0308584A/pt not_active Application Discontinuation
- 2003-03-14 AR ARP030100900A patent/AR036970A1/es not_active Application Discontinuation
- 2003-03-14 IL IL16398103A patent/IL163981A0/xx unknown
- 2003-03-14 TW TW092105579A patent/TWI339122B/zh not_active IP Right Cessation
- 2003-03-14 ZA ZA200407403A patent/ZA200407403B/en unknown
- 2003-03-14 EA EA200401210A patent/EA007431B1/ru unknown
- 2003-03-14 UA UA20040907532A patent/UA80964C2/uk unknown
- 2003-03-14 OA OA1200400248A patent/OA12856A/en unknown
- 2003-03-14 NZ NZ535368A patent/NZ535368A/en not_active IP Right Cessation
-
2004
- 2004-09-09 IL IL163981A patent/IL163981A/en active IP Right Grant
- 2004-10-13 NO NO20044342A patent/NO345056B1/no not_active IP Right Cessation
-
2006
- 2006-02-08 HK HK06101668.3A patent/HK1082677A1/xx not_active IP Right Cessation
-
2009
- 2009-08-19 US US12/543,541 patent/US20090318398A1/en not_active Abandoned
-
2011
- 2011-06-21 US US13/165,545 patent/US20110306582A1/en not_active Abandoned
- 2011-10-26 IL IL215944A patent/IL215944A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20110306582A1 (en) | 2011-12-15 |
| EA200401210A1 (ru) | 2005-08-25 |
| HK1082677A1 (en) | 2006-06-16 |
| IL163981A (en) | 2011-11-30 |
| EA007431B1 (ru) | 2006-10-27 |
| IL215944A (en) | 2014-09-30 |
| NO345056B1 (no) | 2020-09-07 |
| IL215944A0 (en) | 2011-12-29 |
| NO20044342L (no) | 2004-12-06 |
| IL163981A0 (en) | 2005-12-18 |
| TW200412976A (en) | 2004-08-01 |
| US20090318398A1 (en) | 2009-12-24 |
| TWI339122B (en) | 2011-03-21 |
| BR0308584A (pt) | 2005-02-22 |
| ZA200407403B (en) | 2007-09-26 |
| NZ535368A (en) | 2007-06-29 |
| UA80964C2 (en) | 2007-11-26 |
| OA12856A (en) | 2006-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434491T2 (de) | Hautpflaster enthaltend testosteron und gegebenenfalls estrogen | |
| BRPI0407485A (pt) | utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina | |
| AR036970A1 (es) | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BRPI0408153A (pt) | formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo | |
| AR056453A1 (es) | Composiciones con estrogeno y metodos terapeuticos para su uso | |
| Costa et al. | Clinical management of transsexual subjects | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
| NO975586D0 (no) | Transdermal innretning og fremgangsmåte for administrering av 17-deacetyl norgestimat alene eller i kombinasjon med et östrogen | |
| Pearson et al. | Antiestrogen treatment of breast cancer: an overview | |
| DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
| BRPI0510760A (pt) | método para administrar a um paciente uma composição, composição tópica, e, emplastro | |
| Sitruk-Ware | Estrogen therapy during menopause: practical treatment recommendations | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| Almen-Christensson et al. | Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study | |
| AU9551201A (en) | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates | |
| CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
| AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales | |
| BR0311371A (pt) | Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| JP2003528919A5 (es) | ||
| AR014082A1 (es) | Concentrado oral de sertralina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |